‘Why Stop At Insulin?’ Senate Democrats Want More List Price Moves From Pharma

Democratic Senators pushed pharma companies beyond insulin pricing during a 10 May Health, Education, Labor and Pensions Committee hearing that was technically focused on the diabetes drug, offering manufacturers a crucial lesson in concession making: sometimes they get you out of the crosshairs, and sometimes they get you more requests for concessions.

The hearing, held the day before the HELP committee will return to marking up four bipartisan drug pricing bills that largely take aim at pharmacy benefits managers, not pharma, demonstrated that pharma can deflect some – but not all – of the pricing attention to other parts of the supply chain